Made possible by charitable contributions from
Bayer , Astellas / Pfizer . Thank You!

Navigation Tip: Click on blue text that’s underlined and in bold for link to more information.


We hope that the  July 2019 Hot SHEET newsletter from Us TOO finds you doing well.

Summer will fly by and, sooner than we think, it will be September - Prostate Cancer Awareness Month ! Registration is now open at: for the 15 th Annual SEA Blue Chicago Prostate Cancer Walk & Run . SEA is an acronym for S upport, E ducate and A dvocate; and blue is to prostate cancer as pink is to breast cancer. Attend in person, donate to the cause, or register as a virtual mover at no charge if you cannot attend in person but would like to help us fundraise or start your own satellite SEA Blue event in your area. For a glimpse into what makes this event so special for so many people, check out the video . Register by July 31 with code HOTSHEET19 for $5 off your registration!

Join us in welcoming Development Director James Hutson to the staff at Us TOO! The impact of his work will help us expand the scope of services and resources that we provide to the prostate cancer community.

Men with metastatic castration-resistant prostate cancer are invited to consider enrollment in one of two international, Pfizer-sponsored studies of talazoparib, a PARP inhibitor.

  • TALAPRO-1: A phase 2, open-label study of talazoparib in men with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal therapy (NHT). CLICK HERE for more information.
  • TALAPRO-2: A phase 3, randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). CLICK HERE for more information.  

CLICK HERE for an overview of these studies in patient-friendly language. .

The  Us TOO Prostate Cancer Clinical Trial Finder simplifies the process of identifying clinical trials by matching a patient’s profile with relevant clinical trials at no charge. We are excited to share that the  site has been upgraded  to the latest web application version and features a new layout with the option to “Pre-Screen Now” from within the Trial Summary; and a new questionnaire layout for better navigation and easier access from mobile devices. 

If you are the wife or female partner of a man with prostate cancer, we invite you to join a conference call to connect with other women facing similar challenges. Because prostate cancer is a couple's disease, the woman is often subject to her own concerns in addition to those she shares with her partner.  A Forum for Her  is an ongoing series of conference calls and invitation-only Facebook group that provides women with important peer-to-peer support.  CLICK HERE for more information. To register, email  or call 336-842-3578. 

Based on the success of A Forum for Her and requests for a similar service for the gay community, we are pleased to introduce A Prostate Cancer Forum for Gay Men and Their Partners . This ongoing conference call series from Us TOO will provide gay men and their partners with important peer-to-peer support. Regular calls began in late June. CLICK HERE for more information. To register, email  or call 336-842-3578.
Prostate cancer support groups  provide a valuable opportunity to connect with others for education, support and perspective on managing every aspect of the disease – from testing to active surveillance, treatment options and side effect management.  Us TOO has a network of more than 200 support groups in the U.S. and abroad .   We thank all of the support group leaders and encourage men diagnosed with prostate cancer to  find an Us TOO support group .  
Us TOO partners with Answer Cancer Foundation, the first virtual real time audio/visual peer-to-peer support group platform providing online access from a computer, mobile device or telephone. In addition to calls each month focused on high-risk/recurrent/advanced disease, low-risk/intermediate prostate cancer, AnCan is now hosting an Active Surveillance Prostate Cancer virtual support group . Calls will be on the first Wednesday of every month at 8:00 pm Eastern . CLICK HERE for details .
IRONMAN is a registry recruiting 5,000 men with advanced prostate cancer from 9 countries . More than 366,000 men die of prostate cancer globally every year. Research on a man's type of prostate cancer, treatment and side effects will help inform what causes prostate cancer, how to stop or slow its progression, and how to provide the best possible care to enable men to live the best quality life possible. 

The Metastatic Prostate Cancer Project is a nationwide genomic research study for men with metastatic and/or advanced prostate cancer. Patients can join online and participate by sharing their medical information and samples. The project’s goal is to release new data to help researchers better understand metastatic and advanced prostate cancer, and accelerate discoveries.  

We hope that you enjoy a safe and happy July 4 th celebration! Take care and let us know how we can help you with educational resources, support services and personal connections to others in the prostate cancer community.

All the best,

Chuck Strand, Chief Executive Officer
James Hutson, Development Director
Jackie Konieczka, Office Manager
Terri Likowski, Program Director - Support Group Services
Tim Mix, Communications Manager